Human Pharmacology of Mephedrone in Comparison with MDMA
Por:
Papaseit, E, Perez-Mana, C, Mateus, JA, Pujadas, M, Fonseca, F, Torrens, M, Olesti, E, de la Torre, R and Farre, M
Publicada:
1 oct 2016
Resumen:
Mephedrone (4-methylmethcathinone) is a novel psychoactive substance popular among drug users because it displays similar effects to MDMA (3,4-methylenedioxymethamphetamine, ecstasy). Mephedrone consumption has been associated with undesirable effects and fatal intoxications. At present, there is no research available on its pharmacological effects in humans under controlled and experimental administration. This study aims to evaluate the clinical pharmacology of mephedrone and its relative abuse liability compared with MDMA. Twelve male volunteers participated in a randomized, double-blind, crossover, and placebo-controlled trial. The single oral dose conditions were: mephedrone 200 mg, MDMA 100 mg, and placebo. Outcome variables included physiological, subjective, and psychomotor effects, and pharmacokinetic parameters. The protocol was registered in ClinicalTrials.gov (NCT02232789). Mephedrone produced a significant increase in systolic and diastolic blood pressure, heart rate, and pupillary diameter. It elicited stimulant-like effects, euphoria, and well-being, and induced mild changes in perceptions with similar ratings to those observed after MDMA administration although effects peaked earlier and were shorter in duration. Maximal plasma concentration values for mephedrone and MDMA peaked at 1.25 h and 2.00 h, respectively. The elimination half-life for mephedrone was 2.15 h and 7.89 h for MDMA. In a similar manner to MDMA, mephedrone exhibits high abuse liability. Its earlier onset and shorter duration of effects, probably related to its short elimination half-life, could explain a more compulsive pattern of use as described by the users.
Filiaciones:
:
Hosp del Mar, Med Res Inst, Neurosci Res Program IMIM, Integrat Pharmacol & Syst Neurosci Res Grp, Parc Salut Mar, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Hosp Univ Germans Trias & Pujol IGTP, Dept Clin Pharmacol, Carretera Canyet S-N, Badalona 08916, Spain
Perez-Mana, C:
Hosp del Mar, Med Res Inst, Neurosci Res Program IMIM, Integrat Pharmacol & Syst Neurosci Res Grp, Parc Salut Mar, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Mateus, JA:
Hosp del Mar, Med Res Inst, Neurosci Res Program IMIM, Integrat Pharmacol & Syst Neurosci Res Grp, Parc Salut Mar, Barcelona, Spain
Pujadas, M:
Hosp del Mar, Med Res Inst, Neurosci Res Program IMIM, Integrat Pharmacol & Syst Neurosci Res Grp, Parc Salut Mar, Barcelona, Spain
Fonseca, F:
Univ Autonoma Barcelona, Barcelona, Spain
Inst Neuropisquiatria & Adicc, Addict Unit, Barcelona, Spain
IMIM, Barcelona, Spain
Torrens, M:
Univ Autonoma Barcelona, Barcelona, Spain
Inst Neuropisquiatria & Adicc, Addict Unit, Barcelona, Spain
IMIM, Barcelona, Spain
Olesti, E:
Hosp del Mar, Med Res Inst, Neurosci Res Program IMIM, Integrat Pharmacol & Syst Neurosci Res Grp, Parc Salut Mar, Barcelona, Spain
Univ Pompeu Fabra CEXS UPF, Barcelona, Spain
de la Torre, R:
Hosp del Mar, Med Res Inst, Neurosci Res Program IMIM, Integrat Pharmacol & Syst Neurosci Res Grp, Parc Salut Mar, Barcelona, Spain
Univ Pompeu Fabra CEXS UPF, Barcelona, Spain
CIBEROBN, CIBER Fisiopatol Obesidad & Nutr CB06 03, Madrid, Spain
:
Hosp del Mar, Med Res Inst, Neurosci Res Program IMIM, Integrat Pharmacol & Syst Neurosci Res Grp, Parc Salut Mar, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Hosp Univ Germans Trias & Pujol IGTP, Dept Clin Pharmacol, Carretera Canyet S-N, Badalona 08916, Spain
Green Published, Bronze, Green Accepted
|